Full text is available at the source.
The role of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in Chronic obstructive pulmonary disease
How diabetes drugs that affect blood sugar and digestion may relate to chronic lung disease
AI simplified
Abstract
Observational studies indicate that glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 (SGLT2) inhibitors may reduce exacerbations in patients with chronic obstructive pulmonary disease (COPD).
- COPD is often associated with type 2 diabetes mellitus, obesity, and cardiovascular disease, which can worsen patient outcomes.
- GLP-1RAs and SGLT2 inhibitors, originally developed for diabetes and obesity, may also be beneficial for COPD management.
- Common inflammatory pathways among COPD, diabetes, and obesity include macrophage dysfunction and inflammasome activation.
- Potential mechanisms for GLP-1RAs and SGLT2 inhibitors in COPD treatment could involve modulation of inflammation and metabolic control.
- Further randomized controlled trials and mechanistic studies are necessary to validate these findings and clarify how these treatments work.
AI simplified